Literature DB >> 6268998

Vasopressin stimulates release of beta-lipotropin and beta-endorphin in conscious rats as measured by radioimmunoassay of unextracted plasma.

H Anhut, W Knepel, D Nutto, G Hertting.   

Abstract

Using a newly developed radioimmunoassay to determine the beta-endorphin-like immunoreactivity (beta-EI) in unextracted plasma, the effect of vasopressin injections on plasma beta-EI was investigated in conscious rats. Arginine vasopressin caused a dose-dependent increase of plasma beta-EI from 34.5 to 7.8 fmol ml--1 (n = 6) in vehicle-treated animals to 205.0 +/- 36.1 fmol ml--1 (n = 7) after injection of the highest vasopressin dose employed (486 ng/100 g b.w.). In view of the appreciable cross-reactivity of beta-lipotropin (beta-LPH) in the radioimmunoassay used, plasma was extracted and subjected to gel chromatography on a Sephadex G-50 column. On average, about 70% of the beta-EI co-eluted with human beta-LPH and about 30% with human beta-endorphin in plasma extracts obtained from both control and vasopressin-treated rats. No peripheral conversion of human beta-LPH occurred under the experimental conditions, since after i.v. bolus injection of human beta-LPH 97% of the beta-EI comigrated with human beta-LPH during gel filtration. A similar blood pressure increase to that induced by the vasopressin injections, when elicited by noradrenaline or angiotensin II i.v., was not followed by an elevation of plasma beta-EI. These data indicate that vasopressin stimulates beta-lipotropin and beta-endorphin release into the systemic circulation in vivo.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6268998     DOI: 10.1007/bf00507229

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  28 in total

1.  Immunoassay of insulin using a two-antibody system.

Authors:  C R MORGAN; A LAZAROW
Journal:  Proc Soc Exp Biol Med       Date:  1962-05

2.  beta-Endorphin is not detectable in plasma from normal human subjects.

Authors:  T Suda; A S Liotta; D T Krieger
Journal:  Science       Date:  1978-10-13       Impact factor: 47.728

3.  Human plasma immunoreactive lipotropin and adrenocorticotropin in normal subjects and in patients with pituitary-adrenal disease.

Authors:  D T Krieger; A S Liotta; T Suda; A Goodgold; E Condon
Journal:  J Clin Endocrinol Metab       Date:  1979-04       Impact factor: 5.958

4.  Isolation and characterization of the opioid peptides from rat pituitary: beta-endorphin.

Authors:  M Rubinstein; S Stein; S Udenfriend
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

5.  Potentiation by vasopressin of corticotropin release induced by corticotropin-releasing factor.

Authors:  F E Yates; S M Russell; M F Dallman; G A Hodge; S M McCann; A P Dhariwal
Journal:  Endocrinology       Date:  1971-01       Impact factor: 4.736

6.  Modulation of in vitro release of beta-endorphin from the separate lobes of the rat pituitary.

Authors:  R Przewłocki; V Höllt; K H Voigt; A Herz
Journal:  Life Sci       Date:  1979-04-23       Impact factor: 5.037

7.  Common precursor to corticotropins and endorphins.

Authors:  R E Mains; B A Eipper; N Ling
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

8.  beta-Endorphin and adrenocorticotropin are selected concomitantly by the pituitary gland.

Authors:  R Guillemin; T Vargo; J Rossier; S Minick; N Ling; C Rivier; W Vale; F Bloom
Journal:  Science       Date:  1977-09-30       Impact factor: 47.728

9.  Influence of converting enzyme inhibition on the release of vasopressin induced by angiotensin.

Authors:  W Knepel; D K Meyer
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

10.  ANTIBODIES TO BRADYKININ AND ANGIOTENSIN: A USE OF CARBODIIMIDES IN IMMUNOLOGY.

Authors:  T L GOODFRIEND; L LEVINE; G D FASMAN
Journal:  Science       Date:  1964-06-12       Impact factor: 47.728

View more
  5 in total

1.  Plasma concentration and vascular effect of beta-endorphin in spontaneously hypertensive and Wistar Kyoto rats.

Authors:  B Bucher; R Bettermann; P Illes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

2.  Release of beta-lipotropin- and beta-endorphin-like material induced by angiotensin in the conscious rat.

Authors:  U Beuers; G Hertting; W Knepel
Journal:  Br J Pharmacol       Date:  1982-08       Impact factor: 8.739

3.  The effect of naloxone on vasopressin release from rat neurohypophysis incubated in vitro.

Authors:  W Knepel; D K Meyer
Journal:  J Physiol       Date:  1983-08       Impact factor: 5.182

4.  Comparison of the development of experimental pyelonephritis in homozygous brattleboro diabetes insipidus rats, heterozygous control rats and normal Wistar rats.

Authors:  M Güngör; O Anğ; V Uysal; H Sağduyu; D Inanç; M Anğ; H Koyuncuoğlu
Journal:  Infection       Date:  1985 Mar-Apr       Impact factor: 3.553

5.  The effect of isoprenaline on plasma concentrations of immunoreactive beta-endorphin and beta-lipotropin in the conscious rat.

Authors:  W Knepel; H Anhut; D Nutto; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-09       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.